Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 3962-3973

  Patani, Neill ^a,b   Dunbier, Anita K ^a,d   Anderson, Helen ^b   Ghazoui, Zara ^a   Ribas, Ricardo ^b   Anderson, Elizabeth ^c,e   Gao, Qiong ^b   A'hern, Roger ^b   Mackay, Alan ^b   Lindemann, Justin ^c   Wellings, Robert ^c   Walker, Jill ^c   Kuter, Irene ^f   Martin, Lesley Ann ^b   Dowsett, Mitch ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GEFITINIB; TRANSCRIPTION FACTOR SLUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR MARKER;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRI3 GENE; C9ORF140 GENE; CANCER HORMONE THERAPY; CAV1 GENE; CAV2 GENE; CCDC34 GENE; CONTROLLED STUDY; CYP26B1 GENE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ESTROGEN DEPRIVATION THERAPY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FKBP15 GENE; FNTA GENE; GENE; GENE EXPRESSION; GTSE1 GENE; HMGN4 GENE; HUMAN; LOW DRUG DOSE; LRP8 GENE; NRP1 GENE; NSUN2 GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PUM1 GENE; RBMS1 GENE; RECQL4 GENE; SEPP1 GENE; SNAI2 GENE; STRA13 GENE; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DEFICIENCY; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMENOPAUSE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84905498037     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1378     Document Type: Article

References (50)

1. Parker MG. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131-7.
2. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106(Pt 4):1377-88.
3. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990;87:6883-7.
4. Robertson J F R GE, Cheung KL, Pinder S, Ellis IO, Wakeling A. Clinical efficacy of fulvestrant and effects on estrogen receptor levels during first-line endocrine treatment of patients with advanced breast cancer. Breast Cancer Res Treat 2004;88:S236-S7.
5. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
6. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: aprospectivecombined analysis of two multicenter trials. Cancer 2003;98:229-38.
7. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
8. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
9. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052-6.
10. Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007;18:64-9.
11. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70.
12. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13.
13. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.
14. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final analysis of overall survival for the Phase II CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Res 2012;72:90s.
15. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5.
16. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the firstline treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012;136:503-11.
17. Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, et al. Dosedependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 2012;133:237-46.
18. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, et al. Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46.
19. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64:1522-33.
20. Manning DL, Nicholson RI. Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins. Eur J Cancer 1993;29 A: 759-62.
21. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32.
22. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-30.
23. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
24. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
25. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
26. Nicholson RI GJ, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocr Relat Cancer 1995:115-21.
27. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier AK, Anderson H, et al. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery 2011;1:338-51.
28. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22.
29. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, et al. Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 2013;19:2775-86.
30. Available from: www.ebi.ac.uk/arrayexpress. (E-MTAB-887).
31. Available from: www.synapse.org. (Dataset:16243).
32. Available from: www.rock.icr.ac.uk/collaborations/Patani.
33. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 2006;8:R32.
34. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-14.
35. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-44.
36. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol 2012;26:1941-52.
37. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012;26:1252-67.
38. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptoralpha activity and is prognostic in breast cancer. Cancer Research 2009;69:6131-40.
39. Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 2009;61:961-70.
40. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A 2012;109:16654-9.
41. Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, et al. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol 2012;26:1496-507.
42. Patani N, Martin LA, Reis-Filho JS, Dowsett M. The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat 2012;131:1-15.
43. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007;282:22278-88.
44. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006;12:5395-402.
45. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 2011;13:R127.
46. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008;214:25-37.
47. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015-28.
48. Glinka Y, Mohammed N, Subramaniam V, Jothy S, Prud'homme GJ. Neuropilin-1is expressed by breast cancer stem-like cells and is linked to NF-kappaB activation and tumor sphere formation. Biochem Biophys Res Commun 2012;425:775-80.
49. Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, et al. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin Cancer Res 2012;18:6040-8.
50. Robertson JF. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007;12:774-84.